Wilson Sonsini Goodrich & Rosati advised Denali Therapeutics on the deal, while Davis Polk advised the representatives of the several underwriters. Denali Therapeutics, a biopharmaceutical company...
Denali Therapeutics’ $316 Million Public Offering
Prime Medicine’s $175 Million IPO
Wilson Sonsini and Honigman advised Prime Medicine on the deal, while Davis Polk advised the joint book-running managers. Prime Medicine, Inc., a biotechnology company committed to...
European Biotech Acquisition’s $200 Million Combination With Oculis
Davis Polk advised European Biotech Acquisition Corp. on the deal while Cooley and Vischer represented Oculis. European Biotech Acquisition Corp. (EBAC), a SPAC, signed its $200 million...
Immatics’ $110 Million Shares Offering
Davis Polk advised Immatics on the offering while Covington represented underwriters. Immatics N.V. executed its $110 million SEC-registered offering of ordinary shares. The ordinary shares are...
Solid Biosciences’ $75 Million Common Stock PIPE Offering
Davis Polk advised the placement agent, BofA Securities, Inc., in the offering. Solid Biosciences, Inc. executed its private placement of $75 million of common stock. The financing is...
Gamida Cell’s $20 Million Shares Offering
Davis Polk advised the representative of the underwriters in the offering. Gamida Cell Ltd. announced the $20 million SEC-registered follow-on offering of 12,905,000 ordinary shares. The ordinary shares...
Medtronic Global Holdings’ €3.5 Billion Notes Offering
DLA Piper advised Medtronic Global Holdings, while Davis Polk advised the representatives of the several underwriters in the offering. Medtronic Global Holdings S.C.A. executed its offering of...
Roivant Sciences’ $400 Million At-The-Market Offering
Davis Polk advised Roivant Sciences Ltd. in the offering. Roivant Sciences Ltd. announced its at-the-market offering program under which Roivant may issue and sell its common shares...
IDEAYA Biosciences’ $80 Million Common Stock Offering
Latham & Watkins represented IDEAYA, while Davis Polk advised the representatives of the several underwriters in the offering. IDEAYA Biosciences, Inc. (Nasdaq: IDYA) announced the pricing of an...
Immunocore’s $250 Million At-The-Market Offering
Davis Polk advised Jefferies, the sales agent, in the offering. Immunocore Holdings plc announced the SEC-registered at-the-marketing offering program of its American depositary shares (ADSs) representing its ordinary...
Novo Nordisk’s $1.1 Billion Acquisition of Forma Therapeutics
Davis Polk advised Novo Nordisk on the deal while Goodwin Procter represented Forma Therapeutics. Novo Nordisk announced its approximately $1.1 billion acquisition of Forma Therapeutics. Under the...
Assertio’s $70 Million Convertible Senior Notes Offering
Davis Polk advised SVB Securities LLC, the sole initial purchaser, in the offering. Assertio Holdings, Inc. executed the offering of $70 million aggregate principal amount of...